Phenotypic and genotypic heterogeneity are characteristic features of cancer patients. To tackle patients’ heterogeneity, immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches. However, approximately 50% of cancer patients that are eligible for treatment with ICIs will not respond well, which motivates the exploration of immunotherapy in combination with either targeted treatmentsRead More
Immune checkpoints are a normal part of the immune system. It engages when proteins on the surface of immune cells called T cells recognize and bind to partner proteins on other cells, such as some tumor cells. Immune based therapies such as ICIs work by blocking checkpoint proteins from binding with their partner proteins. ThisRead More
2501 Student Center
Satya S. Sahoo, PhD, FAMIA
Activities include journal clubs, colloquium series, ideas labs, and team building.